Navigation Links
QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
Date:9/27/2007

EATONTOWN, N.J., Sept. 27 /PRNewswire-FirstCall/ -- QMed, Inc., (Nasdaq: QMED) today announced it expects to report for the three and nine months ending August 31, 2007 revenue of approximately $10.8 million and $26.6 million and a net loss of approximately $9.2 and $13 million respectively. The Company's cash position as of August 31st, 2007 is approximately $6.4 million net of statutory reserves.

Jane Murray, president and CEO, said, "During the months of July and August, we experienced an unusual spike in the payment of medical claims related to services from prior months. As a result, we will report an increase in our incurred but not reported or paid claims liability (IBNR) for the third quarter ended August 31, 2007. This IBNR estimate will represent approximately 30% of total medical expenses for the nine months ended August 31, 2007 resulting in an MER (medical expense ratio) of approximately 114%. Given both our limited claims history, and the trending of costs that results from a continuous enrollment ramp which is very different from standard Medicare Advantage plans, the implications of these payments on our MER cannot be determined with certainty until we achieve a high completion rate which we estimate will be in December 2007.

"Our more than 12 years experience with Medicare chronics provides critical perspective on these costs. The experience shows that adding to patients' length of time in the program (LOTIP) uniformly has produced strong and beneficial effects on both patient health and costs. This is primarily because it takes time for physician-delivered best practice treatment plans to produce a beneficial population result. Given that, a large majority of our membership enrolled in 20
'/>"/>

SOURCE QMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Northfield Labs Receives FDA Comments
2. Herbal treatment should be estimated
3. Breast Cancer in Men Often Underestimated and Under-treated
4. Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment
5. An Estimated 150 Million Indians Suffer From Arthritis
6. Importance of Retroviral Drugs Underestimated
7. Food Allergies In UK being Grossly Over Estimated
8. Number of Heat-Related Deaths is Underestimated by Over 50%
9. Estimated cost of lifetime AIDS treatment assessed to be $618,900
10. Recurrence of SIDS Overestimated: Study
11. AIDS Incidence in India Far Lower Than Previously Estimated New Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Tampa, Florida (PRWEB) June 03, 2015 ... mobile friendly website yesterday, to make shopping for health ... The improved website has a fresh look and makes ... for medical centers around you. , Now, when ... prices for radiology and surgical procedures) they can see ...
(Date:6/3/2015)... 03, 2015 The Canton Group, a ... with technology, announced today that Tim Dodge has joined ... joins The Canton Group as it implements ... customer engagements. , Tim is a tech industry veteran ... variety of technology companies. Before joining The Canton Group, ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 ... health insurance exchange technology, has announced that CEO Jonathan ... (AHIP) Institute 2015 on June 4, 2015. The ... and digital technologies are disrupting traditional business models in ... new business value. , WHAT: Digital Transformation and ...
Breaking Medicine News(10 mins):Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... pair of new vaccines that not only fight cocaine and ... ,The study was conducted by a team of researchers ... Baylor College of Medicine (BCM). ,As part of ... subjects administered to it. ,Researchers found that study ...
... has shown a decline, thanks to the comprehensive program in ... the 2006 report shows a decline in the smoking ... the past year, smoking decreased among men (from 22.5% to ... declines followed a year-long ad campaign aimed at prompting more ...
... and even dabbled with French, but it was only when ... was established. ,Georgia has an IQ of ... Mensa. ,The youngest daughter of a chief executive and ... on intelligent children as the brightest two-year-old she has ever ...
... GmbH presented the first clinical evidence for the ... for patients suffering from chronic pain at ... Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, ... its kind, combining two analgesic principles, mu-receptor agonism ...
... university researchers has found a new modified drug for Alzheimers ... trials. ,Millions of people suffer from this ... Ghosh, the Purdue professor who led the creation of the ... be the first disease-modifying therapy. It may be able to ...
... Organization (WHO) based Special Programme for Research and ... new strategy for strengthening and expanding research ... ,The strategy builds on the programmes ... and enhancing research capacity in countries where parasitic ...
Cached Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Modified Drug Therapy for Alzheimers Disease 2
(Date:6/3/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... immunotherapies, today announced that it has entered into ... purchase approximately $13.6 million of securities in a ... to such investors an aggregate of 2,469,091 shares ... $5.50 per share. The gross ...
(Date:6/3/2015)... Saudi Arabia , June 3, 2015  Varian Medical Systems ... software for the treatment of cancer, is expanding in the ... strategic operating entity in Saudi Arabia . ... with El Seif Development Group, was officially launched today at ... officer Dow Wilson. "This move represents the ...
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
Breaking Medicine Technology:OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... ANGELES, April 28, 2011 This afternoon, at ... Florida, ( http://www.epilepsy.com/etp/aedtrialxi ) Dr. Christopher DeGiorgio, principal ... of a Phase II randomized double-blind clinical trial ... study was conducted at UCLA and the University ...
... DIEGO, April 28, 2011 ResMed Inc. (NYSE: ... quarter ended March 31, 2011.  Revenue for the quarter ended ... a 12% increase on a constant currency basis) over the ... 31, 2011, income from operations was $64.0 million and net ...
Cached Medicine Technology:Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 2Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 3Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: